Sartorius AG
Company Profile
Business description
Sartorius AG is a leading provider of bioprocessing solutions. Its bioprocess division sells equipment and consumables for upstream and downstream manufacturing of biologic drugs and focuses on single-use technology. Its laboratory products and services division offers a wide range of products for laboratory use, including scales, pipettes, and filtration equipment. As of 2024, the bioprocess and LPS divisions contributed 80% and 20% of revenue, respectively. Bioprocess is housed in its subsidiary Sartorius Stedim Biotech, of which Sartorius AG has a 72% ownership and 83% voting control. The business is geographically diverse, with revenue across Europe, Middle East, and Africa (41% of 2024 sales), the Americas (36%), and Asia-Pacific (23%). We estimate China revenue to be around 10%.
Contact
Otto-Brenner-Strasse 20
GottingenNI37079
DEUT: +49 5513080
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2026
Employees
14,242
Stocks News & Analysis
stocks
Older cohorts the budget losers, not necessarily the ASX listed insurers
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,717.00 | 82.40 | -0.94% |
| CAC 40 | 8,117.42 | 135.66 | 1.70% |
| DAX 40 | 24,737.24 | 336.59 | 1.38% |
| Dow JONES (US) | 49,955.74 | 591.86 | 1.20% |
| FTSE 100 | 10,432.34 | 101.79 | 0.99% |
| HKSE | 25,651.12 | 146.73 | -0.57% |
| NASDAQ | 26,202.77 | 332.06 | 1.28% |
| Nikkei 225 | 59,804.41 | 746.18 | -1.23% |
| NZX 50 Index | 12,761.03 | 213.29 | -1.64% |
| S&P 500 | 7,420.31 | 66.70 | 0.91% |
| S&P/ASX 200 | 8,496.60 | 76.50 | -0.89% |
| SSE Composite Index | 4,162.18 | 7.35 | -0.18% |